<?xml version="1.0" encoding="UTF-8"?>
<p id="para110">The MARIETTA trial is an international, single-arm, phase 2 trial done in 24 hospitals in four countries (Italy, the UK, the Netherlands, and Switzerland; 
 <xref rid="sec1" ref-type="sec">appendix p 2</xref>). The trial assessed the safety and activity of a sequential combination of MATRix (methotrexate, cytarabine, thiotepa, and rituximab)
 <xref rid="bib13" ref-type="bibr">
  <sup>13</sup>
 </xref> followed by RICE (rituximab, ifosfamide, carboplatin, and etoposide) and carmustineâ€“thiotepa conditioned autologous HSCT in patients with diffuse large B-cell lymphoma and secondary CNS involvement at diagnosis or relapse. These treatment combinations were selected following the positive results in primary CNS lymphoma
 <xref rid="bib14" ref-type="bibr">14</xref>, 
 <xref rid="bib15" ref-type="bibr">15</xref>, 
 <xref rid="bib16" ref-type="bibr">16</xref> and relapsed or refractory diffuse large B-cell lymphoma
 <xref rid="bib17" ref-type="bibr">
  <sup>17</sup>
 </xref> (rationale shown in 
 <xref rid="sec1" ref-type="sec">appendix p 4</xref>).
</p>
